Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...

Inadequate supply has created opportunities for bad actors seeking to profit from shortages, high costs and demand ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like peptide-1 agonists) that have upended the ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...